Drug Profile
Gemigliptin - LG Chem
Alternative Names: Gemigliptin tartrate sesquihydrate; Gemiglo®; LC-150444; ZemigloLatest Information Update: 02 Aug 2023
Price :
$50
*
At a glance
- Originator LG Life Sciences
- Developer LG Chem; Sanofi
- Class Antihyperglycaemics; Piperidines; Pyrimidines; Small molecules
- Mechanism of Action Dipeptidyl peptidase 4 inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Marketed Type 2 diabetes mellitus
- Phase II/III Acute kidney injury
Most Recent Events
- 24 Jun 2023 Efficacy and adverse event data from a phase III trial in Type 2 diabetes mellitus presented at the83rd Annual Scientific Sessions of the American Diabetes Association (ADA-2023)
- 30 Nov 2022 LG Chem completes the phase III SOLUTION clinical trial for Type II diabetes mellitus in South Korea (PO) (NCT03842267)
- 28 Aug 2022 No recent reports of development identified for phase-I development in Type-2-diabetes-mellitus(In volunteers) in China (PO, Tablet)